In patients with BCR-ABL-negative myeloproliferative neoplasms (MPN), arterial and venous thromboembolic events (ATE/VTE) occur frequently and have a significant impact on morbidity and mortality [1–3]. The gene discussed is ABL1; the disease is myeloproliferative disorder.